glp-1 for obesity thibodaux Medicare's new demonstration program starts today! Learn more about it at the link in our bio! #medicare #retirement #glp1 #weightloss #turning65 GLP-1 2.0: Where the Next

The trial involved several arms, each targeting a different final maintenance dose (4 mg, 8 mg, and 12 mg), but the initial steps were similar

In clinical trials targeting obese populations, Survodutide demonstrated varying degrees of weight loss across dosages ranging from 0.6 to 4.8 milligrams

Not for human or animal injection or consumption

Inflammatory markers decrease

The emerging data on the broad effects of GLP-1 medications may support a more holistic approach to treating diseases that tend to exacerbate with age

If approved, orforglipron may offer a convenient alternative to injectable therapies that supports early intervention and long-term disease management, helping to meet the preference of millions who favor oral medications. Global submissions for the treatment of obesity or overweight are planned by the end of 2025, with diabetes submissions to follow in 2026